Entrada Therapeutics Inc Stock Ownership - Who owns Entrada Therapeutics?

Insider buying vs selling

Have Entrada Therapeutics Inc insiders been buying or selling?
Natarajan SethuramanChief Scientific Officer2024-07-15638$18.00
Dipal DoshiCEO2024-07-151,600$17.81
Natarajan SethuramanChief Scientific Officer2024-07-12600$18.00
Dipal DoshiCEO2024-07-12300$18.00
Kory James WentworthChief Financial Officer2024-07-081,758$14.95
Dipal DoshiCEO2024-06-131,000$16.17
Peter S. KimDirector2024-06-0311,918$6.06
Natarajan SethuramanChief Scientific Officer2024-05-209,675$15.19
Natarajan SethuramanChief Scientific Officer2024-05-178,305$15.14
Dipal DoshiCEO2024-05-171,200$15.11

1 of 8

TRDA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRDA insiders and whales buy or sell their stock.

TRDA Shareholders

What type of owners hold Entrada Therapeutics Inc stock?
Baker Bros Advisors LP14.41%4,865,819$82.62MInstitution
Baker Bros Advisors LP13.33%4,501,658$76.44MInsider
Mpm Bioventures 2018 LP13.11%4,425,784$75.15MInsider
Mpm Bioventures 2014 LP13.11%4,425,784$75.15MInsider
Todd Foley13.11%4,425,784$75.15MInsider
Mpm Asset Management LLC13.11%4,425,784$75.15MInstitution
5am Venture Management LLC13.06%4,408,379$74.85MInstitution
Roche Holding Ltd8.33%2,813,525$47.77MInsider
Price T Rowe Associates Inc8.16%2,753,357$46.75MInstitution
Redmile Group LLC5.79%1,954,420$33.19MInsider

1 of 3

TRDA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRDA50.28%49.72%Net BuyingNet Buying
APLT82.23%7.92%Net SellingNet Selling
CELC70.86%14.96%Net SellingNet Buying
URGN73.07%26.93%Net BuyingNet Selling

Entrada Therapeutics Stock Ownership FAQ

Who owns Entrada Therapeutics?

Entrada Therapeutics (NASDAQ: TRDA) is owned by 77.10% institutional shareholders, 76.23% Entrada Therapeutics insiders, and 0.00% retail investors. Baker Bros Advisors LP is the largest individual Entrada Therapeutics shareholder, owning 4.50M shares representing 13.33% of the company. Baker Bros Advisors LP's Entrada Therapeutics shares are currently valued at $77.02M.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.